Table 2.
Characteristics of the study group
| Variable | Median (IQR) or n (%) |
|---|---|
| Bilirubin, mg/dL | 1.03 (0.71) |
| Albumin, g/dL | 3.57 (0.55) |
| Platelet count, × | 113 (48) |
| Alpha-fetoprotein, ng/mL | 64.6 (527.4) |
| Presence of encephalopathy | 18 (1.1) |
| Maximum tumor diameter, cm | 2.9 (1.5) |
| Tumor characteristics | |
| Monofocal | 643 (39.9) |
| Bifocal | 543 (33.7) |
| Multifocal | 424 (26.4) |
| Portal vein thrombosis | |
| Present | 122 (7.6) |
| Absent | 1,488 (92.4) |
| Extrahepatic spread | |
| Present | 31 (1.9) |
| Absent | 1,579 (98.1) |
| Performance status | |
| 0 | 1,271 (78.9) |
| 1 | 300 (18.6) |
| 2 | 35 (2.2) |
| 3 | 4 (0.3) |
| Child-Turcotte-Pugh class | |
| A | 1,475 (91.6) |
| B | 135 (8.4) |
| MELD score | 9 (2) |
| BCLC stage | |
| 0 | 178 (11.1) |
| A | 569 (35.3) |
| B | 716 (44.5) |
| C | 147 (9.1) |
1,610 procedures were performed in 1,058 patients. The table reports the characteristics of the patients at the time of each procedure. Therefore, data from the same patient may have been included >1 time. BCLC, Barcelona Clinic Liver Cancer; MELD, model for end-stage liver disease.